Isfahan

The registry focuses on patients with venous thromboembolism VTE, including those often excluded from typical clinical trials such as pregnant women, elderly patients, and those with serious health conditions. It aims to improve medical knowledge and patient care by collecting detailed data on these patients clinical status and treatment outcomes. The project also seeks to develop predictive scores to identify patients at higher risk of complications from thromboembolic disease. This observational registry collects extensive information on patients diagnosed with VTE, including details on coexisting conditions, antithrombotic treatment type, dose, and duration, as well as outcomes during the first three months of therapy. It captures data on VTE recurrences, bleeding complications, and deaths, providing insights into real-world treatment and patient management. Participants provide informed consent and are followed for at least three months to monitor clinical outcomes. The registry supports physicians by giving access to data on patients with similar profiles to help manage complex cases. The main outcomes measured include VTE events and complications over a three-year period, supporting ongoing improvements in patient care and risk assessment.

Dystrophic Epidermolysis Bullosa DEB is a rare genetic skin disease causing fragile skin that blisters and bleeds easily, with severity ranging from mild to life-threatening. It results from mutations affecting collagen VII, which is essential for skin integrity. This trial evaluates the safety and effectiveness of a new cell-free therapy called Ev.FV, derived from mesenchymal stem cell extracellular vesicles, aiming to promote wound healing and skin regeneration in DEB patients. Participants will receive Ev.FV, a biological product containing five factors, through intravenous doses given six times every two weeks. These nanovesicles carry molecules that can reduce inflammation, stimulate skin cell growth, promote blood vessel formation, and potentially repair the skins anchoring structures. The study focuses on patients with chronic wounds sized between 10 and 50 square centimeters and includes assessments over several months to monitor wound healing and skin condition. During the trial, patients will undergo evaluations including wound closure rates measured at day 14, and skin disease activity scores at multiple time points up to six months. Pain levels will also be tracked using a visual scale over 30 days. Researchers will monitor safety, treatment effects, and how well the wounds heal. The total study duration includes follow-up visits to ensure comprehensive observation of the therapys impact.

Researchers are evaluating the effectiveness of adding oral curcumin treatment to intravitreal injections of bevacizumab in patients with diabetic macular edema. This randomized, single-blind clinical trial aims to compare two groups one receiving bevacizumab plus curcumin, and the other receiving bevacizumab plus a placebo. The primary goals are to assess the central thickness and volume of the macula, while also measuring the best visual acuity as a secondary outcome. The study involves two intervention groups. Both groups receive intravitreal injections of bevacizumab at a standard dose of 1.25 mg0.05 ml, administered three times at monthly intervals. In the curcumin group, participants also take oral curcumin tablets twice daily at 40 mg each for three months, starting alongside the bevacizumab treatment. The control group takes matching placebo tablets on the same schedule. Participants will be monitored over a three-month period with assessments of macular thickness, macular volume, and visual acuity. These evaluations help determine the effects of the treatments on diabetic macular edema. Safety and treatment response are tracked throughout the study, which is conducted under medical supervision to ensure participant well-being and adherence to the treatment protocol.

Researchers are investigating the potential of exosomes derived from mesenchymal stem cells MSCs as a treatment for osteoarthritis OA, a joint disorder marked by cartilage damage and inflammation. OA involves increased activity of enzymes like MMP and ADAMTS that degrade the joint matrix. MSCs have been studied for OA due to their ability to release beneficial factors, including exosomes that carry bioactive molecules and anti-inflammatory agents, which may help regulate joint cell behavior and slow OA progression. The study evaluates the effects of allogenic MSC-derived exosomes given through two intra-articular injections into the knees on day 1 and day 90. Participants have moderate to severe OA in both knees Kellgren-Lawrence grade 2 or 3 with mild to moderate pain and swelling. This approach aims to assess the therapeutic potential of these exosome injections over time. Participants will be monitored over 6 months, with evaluations at 1, 3, and 6 months after the first injection. The main outcome measure is the Western Ontario and McMaster University Osteoarthritis Index WOMAC, which assesses pain, stiffness, and physical function. Researchers will observe changes following the initial and second injections, tracking the treatments impact on symptoms and joint health.

Researchers are studying how individual health behaviors and broader societal factors like environment, policies, and health system quality affect health outcomes such as death and the development of chronic diseases. This study also explores genetic influences on non-communicable diseases through both a cross-sectional and a prospective cohort approach. It aims to understand these relationships across different socioeconomic and health resource settings worldwide. Participants are adults aged 35 to 70 years at enrollment. The study involves observing various health-related behaviors, societal determinants including built environment, food and nutrition policies, psychosocial and socioeconomic factors, and tobacco use. Researchers will track the incidence of chronic diseases like cardiovascular disease, cancer, respiratory conditions, diabetes, kidney disease, obesity, hypertension, and injuries over time, without administering any specific treatments. Participants will be followed for an average of 10 years, during which researchers will monitor health events such as new cases of cardiovascular disease and other illnesses, hospitalizations, and mortality. Data will be collected on genetic factors and changes in risk factors like smoking and diet. The study measures the impact of health systems and environmental influences on outcomes. Participants will be involved through regular assessments but will not receive interventions as this is an observational study.

Hemodialysis patients often face challenges such as reduced physical performance, balance problems, and fear of falling, which increase their risk of falls. This trial is evaluating whether a structured eye-exercise program performed during hemodialysis sessions can be delivered safely and consistently. The research aims to explore the potential benefits of eye movement and gaze stability training on physical function, balance, and fall-related concerns in this medically complex population. Participants will be randomly assigned to either the eye exercise group or a control group. Those in the eye exercise group will perform a supervised program targeting oculomotor control, gaze stability, and eye-head coordination during hemodialysis. Each session lasts about 15 to 20 minutes, three times per week for 12 weeks. The control group will receive standard nephrology care and routine activity advice without the eye exercises. Throughout the study, participants will undergo assessments of physical function, mobility, strength, balance, and fear of falling at baseline and after 12 weeks. Researchers will monitor recruitment, retention, adherence, safety, and tolerability during the intervention. The total study period includes 12 weeks of treatment with close supervision and outcome evaluation to determine feasibility and preliminary effects of the eye exercise program.

This research aims to evaluate the effects of 12 weeks of daily 10 mg astaxanthin ASX supplementation on insulin sensitivity, lipid profile, oxidative stress marker Malondialdehyde MDA, severity of hirsutism, and depression in women diagnosed with Polycystic Ovary Syndrome PCOS. PCOS is a common hormonal disorder in women of reproductive age, associated with metabolic dysfunction, infertility, and psychological issues. The study is a randomized, double-blind, placebo-controlled trial conducted in Isfahan, Iran, focusing on women with a BMI between 25 and 35 kgm2. Participants will be randomly assigned to receive either ASX supplements or a placebo capsule daily for 12 weeks. The ASX supplement is produced by Zyest Technology Tarawat Zendig institute and matched by placebo in appearance. Participants will be monitored every two weeks for supplement adherence, and they will be instructed to maintain their usual diet and physical activity levels throughout the study. The trial includes baseline and post-intervention assessments, including blood sampling and questionnaires. During the study, participants will undergo evaluations of anthropometric measurements, dietary intake, physical activity using the International Physical Activity Questionnaire, blood pressure, and biochemical markers such as lipid profile and insulin resistance. The severity of hirsutism will be assessed visually using the modified Ferriman-Gallwey scoring method. Blood samples will be collected at baseline and after 12 weeks for laboratory analysis. Researchers will monitor adherence closely and use several outcome measures to assess the impact of ASX supplementation over the study period.

Keratoconus is an eye condition that causes changes in the shape of the cornea, often affecting both eyes unevenly and leading to vision problems. This research aims to find out how common keratoconus is among children and teenagers worldwide. Researchers believe that the number of people with keratoconus may be higher than previous studies have shown. Participants will have a one-time eye exam using a special imaging device called the Pentacam HR, which creates detailed 3D images of the front part of the eye. During this visit, participants and their parents or guardians will complete a questionnaire about risk factors for keratoconus. This study involves children and adolescents aged 6 to 23 years who are visiting medical centers for reasons other than eye problems. Participants will attend a single visit where the eye imaging test and questionnaire take about 15 minutes. The researchers will use the images and information collected to determine how often keratoconus occurs in this age group. The study is observational, meaning it collects data without providing treatment, and participants will be involved only during this single visit.